In partnership with
November 19, 2025
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
The Supreme Court now has a clean shot at revisiting the federal government’s reach over state-legal cannabis after DOJ declined to file an opening brief in Canna Provisions v. Bondi. This unfolds while Congress swiftly rewrote hemp rules, states scramble to defend or figure out local their markets, and operators try to make sense of a federal posture that contradicts the regulated systems they actually live under. Our emergency episode of The Hybrid breaks down how shutdown politics shaped this moment and why the Court’s silence may matter as much as the government’s.
Today’s edition is supported by Superhuman AI and I Hate It Here, two newsletters reshaping how professionals stay sharp, sane, and ahead of their fields.
🧠 DOJ has nothing to say
🐶 Vets warn the hemp ban will come for CBD treats
🧴 States are trying to figure it all out
Could use a slow news day, honestly.
Go from AI overwhelmed to AI savvy professional
AI keeps coming up at work, but you still don't get it?
That's exactly why 1M+ professionals working at Google, Meta, and OpenAI read Superhuman AI daily.
Here's what you get:
Daily AI news that matters for your career - Filtered from 1000s of sources so you know what affects your industry.
Step-by-step tutorials you can use immediately - Real prompts and workflows that solve actual business problems.
New AI tools tested and reviewed - We try everything to deliver tools that drive real results.
All in just 3 minutes a day
Start here — the day’s most important development, decoded for impact.
📌 What Happened: The Justice Department has waived its right to file an opening brief in Canna Provisions v. Bondi, the petition asking the Supreme Court to reconsider whether Congress can use the Controlled Substances Act to block intrastate, state-regulated cannabis activity. The Solicitor General told the Court the government will only respond if the justices request it, leaving the petitioners’ Commerce Clause arguments sitting on the docket without a federal rebuttal. The companies behind the case argue that the federal framework has drifted so far from its original rationale that Raich no longer fits the modern reality of licensed and tightly regulated markets in dozens of states. Justice Clarence Thomas has already questioned the logic of a “half-in, half-out” federal posture, and the Court has shown interest in revisiting long-standing doctrines when the factual landscape has shifted. DOJ’s choice does not predict an outcome, but it creates a clean procedural lane for the justices to take a closer look at a question that has hovered over the industry for a decade.
💡 Why It Matters: A cert grant would open the door to the first real test of federal marijuana prohibition since the early 2000s, with consequences that extend far beyond the Massachusetts companies that filed the case. Even without a grant, the government’s silence signals a tension inside the administration as it weighs a rescheduling decision that softens enforcement while defending a statute that treats cannabis as contraband everywhere. The case lands at a moment when Congress is rewriting hemp rules, states are revising their own markets, and courts are fielding challenges from companies that operate inside legal frameworks built directly on federal accommodation. That constellation creates an environment where the Court could decide it is time to reevaluate the line between interstate commerce and state sovereignty in this space. If the Court declines to hear it, the unresolved contradictions between state licensing systems and federal statute will harden for another year, forcing regulators and operators to keep working around a federal posture that no longer reflects the industry it governs.
🧠 THC Group Take: The plaintiffs built this case for one audience, and they finally reached it. The Court now has a clean record, an unopposed petition, and a question that touches the foundation of federal drug policy. The harder part is understanding how the justices might approach it once they look past the procedural posture. This Court has stepped into highly charged territory before in matters involving presidential immunity, the reach of federal agencies, and major questions doctrine, and that history shows a willingness to revisit settled assumptions when the factual world has moved. Drug policy sits in a different category because Congress has allowed the Controlled Substances Act to age without modernization, even as state systems have grown into a national industry that no longer resembles the landscape that shaped Raich.
A full constitutional overhaul remains improbable, although the Court could still shape the terrain in a meaningful way. A narrow ruling that limits federal reach in tightly regulated intrastate markets is possible. A signal that Congress must take responsibility for updating the statute is possible. A decision that describes the current patchwork as unworkable is also possible. None of these outcomes hand the industry a sweeping victory, yet each one begins to change the legal footing that regulators and operators rely on.
The Administration’s choice to stay quiet carries its own meaning. A formal defense of the statute would collide with its ongoing rescheduling process, and a sweeping concession would create political problems inside a divided Congress. Silence allows the executive branch to acknowledge a problem without taking ownership of a solution. The Court now sits in the same position. The federal framework no longer matches the world that lawmakers, regulators, and businesses inhabit, and the justices must decide whether to hold the line or create the first real pressure that forces Congress to act. The industry should expect a decision that reshapes expectations without delivering a definitive new model because that is how institutional change usually begins in areas where law and practice have drifted too far apart.
Fast-moving headlines, flagged for what matters.
Tucker Carlson’s new podcast episode features psychiatrist Dr. Daniel Amen, who claims heavy marijuana use creates a “toxic brain pattern” marked by reduced blood flow and impaired long-term function. He focuses on teenagers and leans on years of clinic scan data to argue that chronic use can heighten psychosis risk and weaken motivation. The episode hands prohibition-aligned lawmakers and school boards a polished expert voice at a moment when federal hemp policy and rescheduling fights are reshaping national debate. Cannabis policy remains broadly popular with voters, yet influential figures still push messages that frame cannabis as a threat rather than an industry, and those narratives keep circulating outside the circles where operators and policymakers spend most of their time. The segment shows how quickly these arguments can migrate into hearings, ballot campaigns, and local forums once they hit the right media ecosystem. (The Times of India)
A California veterinarian behind VetCBD is warning that the new federal hemp ban in the Trump spending bill will cut off access to full-spectrum CBD products that many dogs and cats now use for arthritis, epilepsy, pain, and other conditions. The statute’s near-zero THC limits were pitched as a way to shut down gas-station intoxicants, but the practical effect is to make most non-intoxicating hemp formulations economically impossible to produce. That shift will not only squeeze pet wellness brands; it will chill veterinarians who finally gained state-level protection to discuss cannabis with clients and now face fresh federal uncertainty. If this language stands, companion animals become collateral damage in a fight Congress claimed was about youth access and synthetic highs, and the emerging veterinary cannabis framework resets to a legally gray, risk-averse crawl. (Marijuana Moment)
Slumber Sleep Inc., a Denver-based sleep products company, released a pointed statement criticizing the shutdown bill language that would effectively outlaw most hemp-derived cannabinoids, including the non-intoxicating formulations used by more than 200,000 of its customers. The company says the new near-zero THC thresholds and the 0.4 milligram cap would erase full-spectrum, lab-tested products that already move through controlled manufacturing channels, not just the corner-store items that prompted the political backlash. Slumber offers a different path that rests on age limits, accredited lab testing, clear total-THC and cannabinoid labeling, licensed retail channels, and real recall and adverse-event reporting. The core message is that serious brands have already built the guardrails Congress keeps saying it wants. As more companies publish their own regulatory frameworks, it becomes harder for lawmakers to defend a blanket ban when workable, enforceable standards are already on the table. (Fitt Insider)
Ohio House and Senate negotiators have reached a tentative deal on legislation that would ban all “intoxicating” hemp products statewide, explicitly including THC beverages that had been the House’s main red line. Rep. Tex Fischer says the House lost leverage after Congress adopted the federal hemp ban, and now faces a take-it-or-leave-it choice that trades hemp drinks for guarantees on home grow, tax revenue for cities with dispensaries, and expected funding for expungement filing fees. Rep. Jamie Callender is backing the package for locking in voter-approved marijuana provisions but warns it also creates probable-cause exposure for patients and known dispensary customers, inviting new search-and-seizure fights. If this passes, Ohio becomes an early example of how federal hemp policy can tilt state-level negotiations toward blanket bans, even in markets that were on the verge of embracing regulated THC beverages. (Ohio Capital Journal / WEWS)
Columbus City Council President Shannon Hardin posted a tongue-in-cheek video “invoicing” the Ohio General Assembly for $8 million, saying the city has already earned its share of adult-use revenue as a host community. The timing is deliberate because lawmakers are still figuring out how the Marijuana Receipts Fund should work and are rewriting parts of Issue 2 at the same time. Hardin’s message is direct. Columbus wants its money, and it wants clarity. It also shows how quickly local leaders are stepping into a negotiation that will shape Ohio’s market long after the first stores open. (The Columbus Dispatch)
Florida’s Constitution Revision Commission has moved a new adult-use marijuana amendment forward for the 2026 ballot after weeks of legal pressure from activists who accused the body of slow-walking the measure. The commission approved revised language that keeps the core legalization framework intact while tightening provisions around licensing authority and implementation timelines. The shift reflects a political calculation: leaders would rather control the drafting process than risk a court ruling that forces a broader amendment onto the ballot. The path is still long, but this vote suggests that Florida’s establishment sees legalization as inevitable and wants to shape its contours before the campaign machinery turns on. That positions 2026 as a high-stakes test of how Florida balances constitutional language with the interests of existing licensees and a restless voter base. (Florida Phoenix)
Texas Agriculture Commissioner Sid Miller says a full federal ban on hemp-derived THC products misses the mark and that Congress needs to focus on real standards instead of wiping out an entire category. He points out that the shutdown bill, as written, could close thousands of vape and smoke shops across the state and disrupt a market that now includes veterans who rely on hemp products for pain and PTSD. Miller supports a national framework that targets synthetics and keeps intoxicants out of kids’ hands, yet he argues the current language sweeps too broadly and expects lawmakers to revisit it before the deadline. His stance puts him in a pragmatic middle lane inside Texas politics and gives hemp and beverage operators a statewide official who is willing to argue for regulation rather than outright prohibition. (FOX 4 Dallas–Fort Worth)
A Michigan lawmaker is pitching cannabis exports as a way to relieve an industry crushed by oversupply, price compression, and a looming 24% wholesale tax. The idea nods to Oregon and California, where export language already sits idle until federal law or interstate compacts change, which tells you how far the politics are from the legal reality. In Michigan it functions less as a live business plan and more as a pressure release, a way to show struggling operators that someone is at least talking about new outlets. Nice in theory, but without federal movement or binding interstate agreements, it stays a talking point while local taxes, licensing caps, and structural limits do the real work on margins. (Crain’s Detroit Business)
Licensed medical cannabis farmer Errol Whyte says Hurricane Melissa wiped out his one acre of ganja in Claremont, leaving him with losses he expects will run into the millions. Even as he assesses the damage, he is pushing the Cannabis Licensing Authority and the government to step in with support and policy flexibility so licensed farmers in Jamaica’s north and east can scale up and cover shortfalls from harder-hit regions in the southwest. The ask is simple on paper and complicated in practice: he wants a regulator that treats climate shocks and yield risk as shared industry problems rather than individual misfortune. How the CLA responds will signal whether Jamaica intends to treat its medical ganja sector as a strategic agricultural asset that deserves disaster planning and production support, or as a high-risk niche left to sink or swim. (MMJDaily (via Jamaica Observer))
🌍 Germany’s Medical Cannabis Imports Hit Record Highs, Canada And Portugal Still In The Driver’s Seat
New BfArM data shows Germany imported roughly 125,500 pounds of medical cannabis flower and equivalents in Q3 2025, a 19% jump over Q2 and a 176% increase year-over-year, pushing total imports for the first three quarters to more than 315,000 pounds. Canada supplied about 146,000 pounds and Portugal nearly 92,800 pounds through Q3, cementing both as the backbone of Germany’s supply chain while Denmark and a long tail of smaller producers split the rest. The surge comes just weeks after regulators raised the import ceiling to about 424,000 pounds and while Berlin moves to curb telemedicine and online access under amendments to the Medical Cannabis Act. That combination of quota expansion and looming access limits shows how the real market behaves: policymakers talk restraint while the medical channel pulls in industrial-scale volumes that domestic cultivation has never matched. For Canadian and Portuguese exporters, Germany remains the prize market for high-grade GMP flower, but it is also a single-point dependency that will magnify any future pricing resets, prescribing limits, or EU-level friction. (StratCann)
At this week’s IgniteIt Summit in Washington, D.C., nearly every hallway conversation circled the same two topics: the federal hemp crackdown baked into the shutdown deal and a rescheduling process that now feels more distant than the headlines suggested. Speakers framed the new hemp language as a $28 billion shock, with some operators describing the coming year as “Hunger Games” for cannabinoids while others openly cheered the chance to kneecap gray-market competitors. Rescheduling talk was noticeably cooler, with executives like Kim Rivers and Boris Jordan still expressing faith in Trump’s promises even as members of Congress on stage refused to give any sense of timing. The split screen was stark: hemp brands are fighting to survive, cannabis executives are gaming out a federal horizon they cannot see, and investors are quietly modeling another year or two of drift. The real takeaway is that Washington is nowhere near resolving the one-plant question, so the next moves belong to industry factions that decide whether to keep sniping from their corners or finally build a single argument Congress can process. (GreenState)
Disclosure: IgniteIt was previously a partner and sponsor of Policy, Decoded.
The best HR advice comes from those in the trenches. That’s what this is: real-world HR insights delivered in a newsletter from Hebba Youssef, a Chief People Officer who’s been there. Practical, real strategies with a dash of humor. Because HR shouldn’t be thankless—and you shouldn’t be alone in it.
From the hearing room to the comment section — we’re watching it all.
🚌 Kyle Sherman and Flowhub are backing a new docuseries called The Great American Dispensary Tour, sending a branded bus across the country to film how different states, operators, and consumers are building local cannabis culture, starting with Nevada’s mix of Vegas lounges and small-town shops like Winnemucca’s veteran-owned Gold Leaf. It is a reminder that cannabis tourism now lives in the nuances of state-by-state systems, not just the first-mover markets we all flew to a decade ago. (Matador Network)
🏈 Former Tennessee Titans tight end and Denver native Bo Scaife is opening All Pro Cannabis in south Denver, turning his All Pro Farms cultivation into a flagship shop with event space and a podcast studio on West Alameda. He is stepping into a Colorado market where sales have slid by hundreds of millions of dollars and cultivation licenses have thinned, betting that vertical integration plus a personal story, including a “Dear Mamma” strain named for his late mother, can still pull shoppers through the door. (Westword)
🌾 Minnesota Senate Commerce Committee DFL members are blasting the new federal hemp-derived THC cap as an “overbroad and misguided” hit on a well-regulated local industry that now anchors hundreds of beverage brands. They are promising hearings in the new year and pressing the state’s congressional delegation to fix the language, a reminder that Minnesota’s political class is still willing to go to bat for its hemp beverage experiment. (Minnesota Senate DFL)
🌿 Families from Easley, South Carolina who rely on CBD for their kids’ epilepsy and trauma-related pain sat down with Sen. Lindsey Graham to plead for changes to the new federal hemp limits, warning that a 0.4 milligram cap would wipe out the safe products they use while doing little to stop bad actors. Graham called hemp “very good or very bad” and said he will use the one-year implementation window to consult law enforcement, families, and farmers on fixes, signaling that the ban language is not politically settled yet. (WYFF 4 Greenville)
🧪 Congress quietly rewrote hemp chemistry in the shutdown deal, counting all THC compounds in a product and stripping “hemp” status from anything with synthetic cannabinoids added. Scientists note there is almost no safety data on many of these analogs, yet the 0.4 milligram cap risks sweeping up legitimate CBD tinctures where trace THC appears as an impurity. (Chemical & Engineering News)